Breast cancer: Aromatase inhibitors--bone health assessment is crucial.

Suppr

超能文献

作者信息

Hadji Peyman

出版信息

Nat Rev Clin Oncol. 2012 Mar 27;9(5):254-5. doi: 10.1038/nrclinonc.2012.47.

DOI:10.1038/nrclinonc.2012.47

PMID:22450194

Abstract

摘要

相似文献

Breast cancer: Aromatase inhibitors--bone health assessment is crucial.

Nat Rev Clin Oncol. 2012 Mar 27;9(5):254-5. doi: 10.1038/nrclinonc.2012.47.

Markers of bone metabolism in women receiving aromatase inhibitors for early-stage breast cancer.

Clin Breast Cancer. 2009 May;9(2):72-6. doi: 10.3816/CBC.2009.n.014.

Managing bone mineral density with oral bisphosphonate therapy in women with breast cancer receiving adjuvant aromatase inhibition.管理乳腺癌女性接受辅助芳香酶抑制治疗时的口服双膦酸盐治疗的骨密度。

Breast Cancer Res. 2010;12(3):110. doi: 10.1186/bcr2584. Epub 2010 Jun 18.

Aromatase inhibitors and bone health in women with breast cancer.芳香化酶抑制剂与乳腺癌女性的骨骼健康

J Clin Oncol. 2006 Nov 20;24(33):5305-12. doi: 10.1200/JCO.2006.07.5382.

Bone health management of Australian breast cancer survivors receiving hormonal therapy.接受激素治疗的澳大利亚乳腺癌幸存者的骨骼健康管理

Intern Med J. 2015 Nov;45(11):1182-5. doi: 10.1111/imj.12897.

Managing bone health in women with breast cancer under adjuvant treatment with aromatase inhibitors: pretreatment bone mineral density is important.

Breast Cancer Res. 2010;12(4):403. doi: 10.1186/bcr2609. Epub 2010 Aug 3.

Aromatase inhibitors and bone health.芳香化酶抑制剂与骨骼健康。

Curr Opin Obstet Gynecol. 2009 Feb;21(1):60-7. doi: 10.1097/GCO.0b013e32831da80e.

Changes in bone mineral density after adjuvant aromatase inhibitors and fracture risk in breast cancer patients.辅助性芳香化酶抑制剂治疗后乳腺癌患者的骨矿物质密度变化及骨折风险

J Clin Oncol. 2007 Apr 10;25(11):1455-6. doi: 10.1200/JCO.2006.08.7080.

[Expert group consensus: prevention, diagnosis and treatment of bone loss and osteoporosis in postmenopausal breast cancer patients after aromatase inhibitor therapy].[专家小组共识：芳香化酶抑制剂治疗后绝经后乳腺癌患者骨质流失和骨质疏松的预防、诊断与治疗]

Zhonghua Zhong Liu Za Zhi. 2013 Nov;35(11):876-9.

[A prospective study of bone loss in early stage postmenopausal breast cancer treated with aromatase inhibitors].[芳香化酶抑制剂治疗绝经后早期乳腺癌骨丢失的前瞻性研究]

Zhonghua Zhong Liu Za Zhi. 2020 May 23;42(5):403-407. doi: 10.3760/cma.j.cn112152-112152-20191112-00728.

引用本文的文献

Quality of life in MAP.3 (Mammary Prevention 3): a randomized, placebo-controlled trial evaluating exemestane for prevention of breast cancer.MAP.3（乳腺预防 3）试验中的生活质量：一项评估依西美坦用于预防乳腺癌的随机、安慰剂对照试验。

J Clin Oncol. 2014 May 10;32(14):1427-36. doi: 10.1200/JCO.2013.51.2483. Epub 2014 Apr 7.

本文引用的文献

Bone density and structure in healthy postmenopausal women treated with exemestane for the primary prevention of breast cancer: a nested substudy of the MAP.3 randomised controlled trial.在接受依西美坦进行乳腺癌初级预防的健康绝经后妇女中，骨密度和结构：MAP.3 随机对照试验的嵌套子研究。

Lancet Oncol. 2012 Mar;13(3):275-84. doi: 10.1016/S1470-2045(11)70389-8. Epub 2012 Feb 7.

Management of aromatase inhibitor-associated bone loss in postmenopausal women with breast cancer: practical guidance for prevention and treatment.乳腺癌绝经后妇女芳香化酶抑制剂相关骨丢失的管理：预防和治疗的实用指南。

Ann Oncol. 2011 Dec;22(12):2546-2555. doi: 10.1093/annonc/mdr017. Epub 2011 Mar 17.

Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial.早期乳腺癌中辅助他莫昔芬和依西美坦（TEAM）的研究：一项随机 3 期试验。

Lancet. 2011 Jan 22;377(9762):321-31. doi: 10.1016/S0140-6736(10)62312-4.

The effect of exemestane and tamoxifen on bone health within the Tamoxifen Exemestane Adjuvant Multinational (TEAM) trial: a meta-analysis of the US, German, Netherlands, and Belgium sub-studies.依西美坦与他莫昔芬对 Tamoxifen Exemestane Adjuvant Multinational（TEAM）试验中骨健康的影响：美国、德国、荷兰和比利时亚研究的荟萃分析。

J Cancer Res Clin Oncol. 2011 Jun;137(6):1015-25. doi: 10.1007/s00432-010-0964-y. Epub 2010 Dec 18.

The effect of exemestane or tamoxifen on markers of bone turnover: results of a German sub-study of the Tamoxifen Exemestane Adjuvant Multicentre (TEAM) trial.依西美坦或他莫昔芬对骨转换标志物的影响：他莫昔芬依西美坦辅助多中心（TEAM）试验德国子研究的结果

Breast. 2009 Jun;18(3):159-64. doi: 10.1016/j.breast.2009.03.003. Epub 2009 Apr 11.

Aromatase inhibitor-associated bone loss in breast cancer patients is distinct from postmenopausal osteoporosis.芳香化酶抑制剂相关的乳腺癌患者骨质流失不同于绝经后骨质疏松症。

Crit Rev Oncol Hematol. 2009 Jan;69(1):73-82. doi: 10.1016/j.critrevonc.2008.07.013. Epub 2008 Aug 30.

Effects of steroidal and nonsteroidal aromatase inhibitors on markers of bone turnover in healthy postmenopausal women.甾体和非甾体芳香化酶抑制剂对健康绝经后妇女骨转换标志物的影响。

Breast Cancer Res. 2007;9(4):R52. doi: 10.1186/bcr1757.

Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial.他莫昔芬治疗2 - 3年后依西美坦与他莫昔芬的生存情况及安全性比较（国际依西美坦研究组）：一项随机对照试验

Lancet. 2007 Feb 17;369(9561):559-70. doi: 10.1016/S0140-6736(07)60200-1.

Effect of an aromatase inhibitor on bmd and bone turnover markers: 2-year results of the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) trial (18233230).一种芳香化酶抑制剂对骨密度和骨转换标志物的影响：阿那曲唑、他莫昔芬单独或联合使用（ATAC）试验的2年结果（18233230）

J Bone Miner Res. 2006 Aug;21(8):1215-23. doi: 10.1359/jbmr.060508.

Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17.来曲唑与安慰剂对完成5年或更长时间辅助性他莫昔芬治疗的原发性乳腺癌女性骨密度的影响：NCIC CTG MA.17的一项配套研究

J Clin Oncol. 2006 Aug 1;24(22):3629-35. doi: 10.1200/JCO.2005.05.4882. Epub 2006 Jul 5.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验